Update on molecular pathology of cutaneous melanocytic lesions: What is new in diagnosis and molecular testing for treatment?

Frontiers in Medicine

Volumn 1, Issue OCT, 2014, Pages 1-1

  van Engen van Grunsven, Adriana C H ^a   Kusters Vandevelde, Heidi ^b   Groenen, Patricia J T A ^a   Blokx, Willeke A M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

Congenital nevus; Melanoma; Molecular pathology; Review; Spitz; Targeted therapy

Indexed keywords

EID: 84987906644     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2014.00039     Document Type: Article

References (75)

1. Blokx WA, van Dijk MC, Ruiter DJ. Molecular cytogenetics of cutaneous melanocytic lesions-diagnostic, prognostic and therapeutic aspects. Histopathology (2010) 56:121-32. doi: 10.1111/j.1365-2559.2009.03452.x
2. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 353:2135-47. doi:10.1056/NEJMoa050092
3. Solus JF, Kraft S. Ras, Raf, and MAP kinase in melanoma. Adv Anat Pathol (2013) 20:217-26. doi:10.1097/PAP.0b013e3182976c94
4. Takata M, Murata H, Saida T. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma. Pigment Cell Melanoma Res (2010) 23:64-71. doi:10.1111/j.1755-148X.2009.00645.x
5. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res (2011) 24:879-97. doi:10.1111/j.1755-148X.2011.00880.x
6. Ichii-Nakato N, Takata M, Takayanagi S, Takashima S, Lin J, Murata H, et al. High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. J Invest Dermatol (2006) 126:2111-8. doi:10.1038/sj.jid.5700366
7. Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol (2014) 9:239-71. doi:10.1146/annurev-pathol-012513-104658
8. Bauer J, Curtin JA, Pinkel D, Bastian BC. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol (2007) 127:179-82. doi:10.1038/sj.jid.5700490
9. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2009) 457:599-602. doi:10.1038/nature07586
10. van Dijk MC, Bernsen MR, Ruiter DJ. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. Am J Surg Pathol (2005) 29:1145-51. doi:10.1097/01.pas.0000157749.18591.9e
11. Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, et al. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn (2013) 15:220-6. doi:10.1016/j.jmoldx.2012.10.002
12. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One (2012) 7:e35309. doi:10.1371/journal.pone.0035309
13. van Engen-van Grunsven AC, van Dijk MC, Ruiter DJ, Klaasen A, Mooi WJ, Blokx WA. HRAS-mutated Spitz tumors: a subtype of Spitz tumors with distinct features. Am J Surg Pathol (2010) 34:1436-41. doi:10.1097/PAS.0b013e3181f0a749
14. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 43:1018-21. doi:10.1038/ng.910
15. Busam KJ, Wanna M, Wiesner T. Multiple epithelioid Spitz nevi or tumors with loss of BAP1 expression: a clue to a hereditary tumor syndrome. JAMA Dermatol (2013) 149:335-9. doi:10.1001/jamadermatol.2013.1529
16. Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun (2014) 5:3116. doi:10.1038/ncomms4116
17. Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol (2000) 157:967-72. doi:10.1016/S0002-9440(10)64609-3
18. Da Forno PD, Pringle JH, Fletcher A, Bamford M, Su L, Potter L, et al. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance. Br J Dermatol (2009) 161:364-72. doi:10.1111/j.1365-2133.2009.09181.x
19. Richetta AG, Silvestri V, Giancristoforo S, Rizzolo P, D'Epiro S, Graziano V, et al. Mutational profiling in melanocytic tumors: multiple somatic mutations and clinical implications. Oncology (2014) 86:104-8. doi:10.1159/000356878
20. Wiesner T, Murali R, Fried I, Cerroni L, Busam K, Kutzner H, et al. A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol (2012) 36:818-30. doi:10.1097/PAS.0b013e3182498be5
21. Yeh I, Mully TW, Wiesner T, Vemula SS, Mirza SA, Sparatta AJ, et al. Ambiguous melanocytic tumors with loss of 3p21. Am J Surg Pathol (2014) 38(8):1088-95. doi:10.1097/PAS.0000000000000209
22. Pouryazdanparast P, Haghighat Z, Beilfuss BA, Guitart J, Gerami P. Melanocytic nevi with an atypical epithelioid cell component: clinical, histopathologic, and fluorescence in situ hybridization findings. Am J Surg Pathol (2011) 35:1405-12. doi:10.1097/PAS.0b013e31822678d2
23. Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol (2014) 25:234-9. doi:10.1097/ICU.0000000000000051
24. Yu H, Pak H, Hammond-Martel I, Ghram M, Rodrigue A, Daou S, et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci U S A (2014) 111:285-90. doi:10.1073/pnas.1309085110
25. Ismail IH, Davidson R, Gagne JP, Xu ZZ, Poirier G, Hendzel MJ. Germ-line mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res (2014) 74(16):4282-94. doi:10.1158/0008-5472.CAN-13-3109
26. Dey A, Seshasayee D, Noubade R, French DM, Liu J, Chaurushiya MS, et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science (2012) 337:1541-6. doi:10.1126/science.1221711
27. Carbone M, Ferris LK, Baumann F, Napolitano A, Lum CA, Flores EG, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med (2012) 10:179. doi:10.1186/1479-5876-10-179
28. Busam KJ, Kutzner H, Cerroni L, Wiesner T. Clinical and pathologic findings of Spitz nevi and atypical spitz tumors with ALK fusions. Am J Surg Pathol (2014) 38:925-33. doi:10.1097/PAS.0000000000000187
29. Marino-Enriquez A, Dal Cin P. ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. Cancer Genet (2013) 206:357-73. doi:10.1016/j.cancergen.2013.07.001
30. Krengel S. Nevogenesis-new thoughts regarding a classical problem. Am J Dermatopathol (2005) 27:456-65. doi:10.1097/01.dad.0000175532.27368.3f
31. Ruiz-Maldonado R. Measuring congenital melanocytic nevi. Pediatr Dermatol (2004) 21:178-9. doi:10.1111/j.0736-8046.2004.21222.x
32. Danarti R, Konig A, Happle R. Large congenital melanocytic nevi may reflect paradominant inheritance implying allelic loss. Eur J Dermatol (2003) 13:430-2
33. de Wijn RS, Zaal LH, Hennekam RC, van der Horst CM. Familial clustering of giant congenital melanocytic nevi. J Plast Reconstr Aesthet Surg (2010) 63:906-13. doi:10.1016/j.bjps.2009.02.090
34. Krengel S, Hauschild A, Schafer T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol (2006) 155:1-8. doi:10.1111/j.1365-2133.2006.07218.x
35. Dessars B, De Raeve LE, Morandini R, Lefort A, El Housni H, Ghanem GE, et al. Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. J Invest Dermatol (2009) 129:139-47. doi:10.1038/jid.2008.203
36. Dessars B, De Raeve LE, El Housni H, Debouck CJ, Sidon PJ, Morandini R, et al. Chromosomal translocations as a mechanism of BRAF activation in two cases of large congenital melanocytic nevi. J Invest Dermatol (2007) 127:1468-70. doi:10.1038/sj.jid.5700725
37. Charbel C, Fontaine RH, Malouf GG, Picard A, Kadlub N, El-Murr N, et al. NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi. J Invest Dermatol (2014) 134:1067-74. doi:10.1038/jid.2013.429
38. Kinsler VA, Thomas AC, Ishida M, Bulstrode NW, Loughlin S, Hing S, et al. Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol (2013) 133(9):2229-36. doi:10.1038/jid.2013.70
39. Kinsler V, Shaw AC, Merks JH, Hennekam RC. The face in congenital melanocytic nevus syndrome. Am J Med Genet A (2012) 158A:1014-9. doi:10.1002/ajmg.a.34217
40. Zenker M. Clinical manifestations of mutations in RAS and related intracellular signal transduction factors. Curr Opin Pediatr (2011) 23:443-51. doi:10.1097/MOP.0b013e32834881dd
41. Kinsler VA, Abu-Amero S, Budd P, Jackson IJ, Ring SM, Northstone K, et al. Germline melanocortin-1-receptor genotype is associated with severity of cutaneous phenotype in congenital melanocytic nevi: a role for MC1R in human fetal development. J Invest Dermatol (2012) 132:2026-32. doi:10.1038/jid.2012.95
42. Kadonaga JN, Frieden IJ. Neurocutaneous melanosis: definition and review of the literature. J Am Acad Dermatol (1991) 24:747-55. doi:10.1016/0190-9622(91)70115-I
43. Pedersen M, Kusters-Vandevelde HV, Viros A, Groenen PJ, Sanchez-Laorden B, Gilhuis JH, et al. Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. Cancer Discov (2013) 3:458-69. doi:10.1158/2159-8290.CD-12-0464
44. Hafner C, Groesser L. Mosaic RASopathies. Cell Cycle (2013) 12:43-50. doi:10.4161/cc.23108
45. Avitan-Hersh E, Tatur S, Indelman M, Gepstein V, Shreter R, Hershkovitz D, et al. Postzygotic HRAS mutation causing both keratinocytic epidermal nevus and thymoma and associated with bone dysplasia and hypophosphatemia due to elevated FGF23. J Clin Endocrinol Metab (2014) 99:E132-6. doi:10.1210/jc.2013-2813
46. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 14:249-56. doi:10.1016/S1470-2045(13)70024-X
47. Kusters-Vandevelde HV, Willemsen AE, Groenen PJ, Kusters B, Lammens M, Wesseling P, et al. Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor. Acta Neuropathol Commun (2014) 2:41. doi:10.1186/2051-5960-2-41
48. Banerjee SS, Harris M. Morphological and immunophenotypic variations in malignant melanoma. Histopathology (2000) 36:387-402. doi:10.1046/j.1365-2559.2000.00894.x
49. Banerjee SS, Eyden B. Divergent differentiation in malignant melanomas: a review. Histopathology (2008) 52:119-29
50. Bearman RM, Noe J, Kempson RL. Clear cell sarcoma with melanin pigment. Cancer (1975) 36:977-84. doi:10.1002/1097-0142(197509)36:3<977::AID-CNCR2820360321>3.0.CO;2-D
51. Enzinger FM. Clear-cell sarcoma of tendons and aponeuroses. An analysis of 21 cases. Cancer. (1965) 18:1163-74
52. Hantschke M, Mentzel T, Rutten A, Palmedo G, Calonje E, Lazar AJ, et al. Cutaneous clear cell sarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 12 cases emphasizing its distinction from dermal melanoma. Am J Surg Pathol (2010) 34:216-22. doi:10.1097/PAS.0b013e3181c7d8b2
53. Mrozek K, Karakousis CP, Perez-Mesa C, Bloomfield CD. Translocation t(12;22)(q13;q12.2-12.3) in a clear cell sarcoma of tendons and aponeuroses. Genes Chromosomes Cancer (1993) 6:249-52. doi:10.1002/gcc.2870060412
54. Antonescu CR, Nafa K, Segal NH, Dal Cin P, Ladanyi M. EWS-CREB1: a recurrent variant fusion in clear cell sarcoma-association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res (2006) 12:5356-62. doi:10.1158/1078-0432.CCR-05-2811
55. Yang L, Chen Y, Cui T, Knosel T, Zhang Q, Geier C, et al. Identification of biomarkers to distinguish clear cell sarcoma from malignant melanoma. Hum Pathol (2012) 43:1463-70. doi:10.1016/j.humpath.2011.10.022
56. Bekers EM, van Engen-van Grunsven AC, Groenen PJ, Westdorp H, Koornstra RH, Bonenkamp JJ, et al. Metastatic melanoma mimicking solitary fibrous tumor: report of two cases. Virchows Arch (2014) 464:247-51. doi:10.1007/s00428-014-1542-5
57. King R, Busam K, Rosai J. Metastatic malignant melanoma resembling malignant peripheral nerve sheath tumor: report of 16 cases. Am J Surg Pathol (1999) 23:1499-505. doi:10.1097/00000478-199912000-00007
58. Lodding P, Kindblom LG, Angervall L. Metastases of malignant melanoma simulating soft tissue sarcoma. A clinico-pathological, light-and electron microscopic and immunohistochemical study of 21 cases. Virchows Arch A Pathol Anat Histopathol (1990) 417:377-88. doi:10.1007/BF01606026
59. Zelger BG, Steiner H, Wambacher B, Zelger B. Malignant melanomas simulating various types of soft tissue tumors. Dermatol Surg (1997) 23:1047-54. doi:10.1111/j.1524-4725.1997.tb00446.x
60. Magro CM, Crowson AN, Mihm MC. Unusual variants of malignant melanoma. Mod Pathol (2006) 19(Suppl 2):S41-70. doi:10.1038/modpathol.3800516
61. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol (2012) 30:2522-9. doi:10.1200/JCO.2011.41.2452
62. Piccinin S, Doglioni C, Maestro R, Vukosavljevic T, Gasparotto D, D'Orazi C, et al. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int J Cancer (1997) 74:26-30. doi:10.1002/(SICI)1097-0215(19970220)74:1<26::AID-IJC5>3.0.CO;2-2
63. Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med (1998) 338:879-87. doi:10.1056/NEJM199803263381305
64. Crowson AN, Magro CM, Mihm MC. The Melanocytic Proliferations. New York, NY: Wiley-Liss (2001)
65. Colombino M, Lissia A, Capone M, De Giorgi V, Massi D, Stanganelli I, et al. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. J Transl Med (2013) 11:202. doi:10.1186/1479-5876-11-202
66. Blokx WA, Lesterhuis WJ, Andriessen MP, Verdijk MA, Punt CJ, Ligtenberg MJ. CDKN2A (INK4A-ARF) mutation analysis to distinguish cutaneous melanoma metastasis from a second primary melanoma. Am J Surg Pathol (2007) 31:637-41. doi:10.1097/PAS.0b013e318030718d
67. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ-and GNA11-dependent manner. Clin Cancer Res (2012) 18:4345-55. doi:10.1158/1078-0432.CCR-11-3227
68. Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, et al. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One (2012) 7:e40439. doi:10.1371/journal.pone.0040439
69. Saint-Jean M, Quereux G, Nguyen JM, Peuvrel L, Brocard A, Vallee A, et al. Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy? J Invest Dermatol (2014) 134:1468-70. doi:10.1038/jid.2013.378
70. Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med (2010) 8:67. doi:10.1186/1479-5876-8-67
71. Amanuel B, Grieu F, Kular J, Millward M, Iacopetta B. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology (2012) 44:357-9. doi:10.1097/PAT.0b013e3283532565
72. Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF, Long GV. BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer (2012) 49(5):1073-9. doi:10.1016/j.ejca.2012.11.004
73. Menzies AM, Long GV, Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther (2012) 6:391-405. doi:10.2147/DDDT.S38998
74. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 140:209-21. doi:10.1016/j.cell.2009.12.040
75. Stones CJ, Kim JE, Joseph WR, Leung E, Marshall ES, Finlay GJ, et al. Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Front Genet (2013) 4:66. doi:10.3389/fgene.2013.00066